Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
18
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs on pharmaceutical manufacturing and supply of medicines to patients globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | PFAS restrictions (Legislation) | 1 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Exchange about the burden of sickle-cell disease in Europe and the Pfizer-supported call to action Shaping the Change for Sickle Cell Disease Patients in Europe and Beyond. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | EU Affairs | Urban Wastewater Treatment Directive (UWWTD) (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Migraine Summit (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | Potential EU proposals to restrict use of titanium dioxide and PFAS in medicines (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 3 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | European System of Accounts (EU Accounting Rules) (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Trade | Highlight importance of IP rights and understand EP actions on possible TRIPS waiver proposal; discuss EU Pharmaceutical Strategy and importance of free trade in medicines and vaccines. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Pfizer | Health | Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Pfizer | EU Affairs | The EU Commission is introducing legislation for an SPC (Supplementary Protection Certificate) ‘export exemption’; this would allow companies to manufacture products that have an SPC within the EU for export outside the… (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Taxation | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 21 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2015 | Pfizer | EU Affairs | ‘On the Fight Against Breast Cancer in the European Union’ (Public policy or programme) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| EU Affairs | 10 | 55.6% | |
| Health | 5 | 27.8% | |
| Trade | 2 | 11.1% | |
| Taxation | 1 | 5.6% |